Ratings Yunkang Group Limited

Equities

2325

KYG9889T1067

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
11.12 ^HKD	+0.36%		+0.54%	-9.59%

Apr. 05	Everbest Machinery Industry to Set Up 30 Million Yuan Joint Venture	MT
Mar. 26	Yunkang Swings to Loss in 2023; Recommends Dividend	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company sustains low margins.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
YUNKANG GROUP LIMITED	-9.59%	854M	-
SONIC HEALTHCARE LIMITED	-17.89%	8.25B	B+
RADNET, INC.	+39.20%	3.57B	C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B	B-
SYNLAB AG	-8.06%	2.46B	-
DR. LAL PATHLABS LIMITED	-7.35%	2.38B	B-
NEOGENOMICS, INC.	-12.61%	1.81B	C-
FLEURY S.A.	-19.01%	1.55B	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B	C+
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes